# Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）

> **NCT05429463** · PHASE3 · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 250 (estimated)

## Conditions studied

- Squamous Cell Non-small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Sintilimab
- **DRUG:** Carboplatin
- **DRUG:** Albumin-Bound Paclitaxel

## Key facts

- **NCT ID:** NCT05429463
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-11
- **Primary completion:** 2025-11-11
- **Final completion:** 2029-11-11
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2022-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05429463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05429463, "Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05429463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*